The US Food and Drug Administration warned against giving a controversial drug to patients who are also getting the one drug that has any authorization for use in treating coronavirus.
Mixing remdesivir and either chloroquine or hydroxychloroquine could reduce the effectiveness of remdesivir, the FDA warned. Earlier on Monday, the FDA removed the emergency use authorization it had given the two malaria drugs, leaving remdesivir as the only drug that has the authorization for Covid-19.
“The agency is not aware of instances of this reduced activity occurring in the clinical setting but is continuing to evaluate all data related to remdesivir,” the FDA said.
More on this: Hydroxychloroquine and chloroquine were touted by President Trump as good drugs to take to treat coronavirus, and he said last month that he himself was taking hydroxychloroquine to prevent coronavirus infection.
Several studies have shown not only that the drugs do not help patients with Covid-19, but they might raise the risk of serious side-effects.
On Monday, the FDA said the drugs do not meet "the statutory criteria" for emergency use authorization as they are unlikely to be effective in treating Covid-19 based on the latest scientific evidence.
Remdesivir is an infused antiviral drug made by Gilead Sciences Inc.